The aim of this study is to evaluate the prophylactic effects of probiotic mixture BIFICO on antibiotic-induced gut dysbiosis (AIGD) and the influence on the change of the gut microbiota. We conducted a prospective, randomized, controlled study and divided 196 patients who required intravenous beta-lactam antibiotics into three groups: a control group (no probiotics), a regular group (840 mg of BIFICO), and a double-dosage group (1680 mg of BIFICO). The symptoms of antibiotic-related diarrhea, bloating and abdominal pain and the incidence of AIGD were evaluated 7 days and 8–14 days after antibiotic use, with 10 patients in each group. 16S rDNA sequencing was performed to detect changes of the gut microbiota. Within 7 days of the initiation of antibiotic treatment, the incidences of AIGD in the control group, regular group (840 mg of BIFICO), and double-dosage group (1680 mg of BIFICO) were 21.88%, 14.93%, and 6.15% respectively. On days of 8–14th, the incidences of AIGD in the control group, regular group, and double-dosage group were 25%, 14.93%, and 4.62%, respectively. The incidence of AIGD in the double-dosage group within 7 days and 14 days were both significantly lower than that in relevant control group (P < 0.05). On day 14, the incidence of AIGD in the double-dosage group was lower than that in the regular group (P < 0.05). The number of operational taxonomic units (OTUs) in the control group after antibiotic treatment was significantly reduced compared to that prior to treatment, while those of the regular and double-dosage groups were stable. The species abundance, especially Parabacteroides, Phascolarctobacterium and Roseburia, of the double-dosage group was greater than that of the regular group and the control group. BIFICO may reduce the occurrence of AIGD in a dose-dependent manner and can stabilize the gut microbiota balance.

中文翻译：

---

BIFICO 对抗生素引起的肠道菌群失调和肠道菌群的预防作用。

本研究的目的是评估益生菌混合物 BIFICO 对抗生素诱导的肠道菌群失调 (AIGD) 的预防作用以及对肠道菌群变化的影响。我们进行了一项前瞻性、随机、对照研究，将 196 名需要静脉注射 β-内酰胺类抗生素的患者分为三组：对照组（无益生菌）、常规组（840 mg BIFICO）和双剂量组（1680毫克 BIFICO）。在抗生素使用后 7 天和 8-14 天评估抗生素相关性腹泻、腹胀和腹痛的症状以及 AIGD 的发生率，每组 10 名患者。进行 16S rDNA 测序以检测肠道微生物群的变化。在开始抗生素治疗的 7 天内，对照组、常规组（840 mg BIFICO）的 AIGD 发生率，和双剂量组（1680 mg BIFICO）分别为 21.88%、14.93% 和 6.15%。第8~14天，对照组、常规组和双剂量组AIGD发生率分别为25%、14.93%和4.62%。双剂量组7 d和14 d内AIGD发生率均显着低于相关对照组（P < 0.05）。第14天，双剂量组AIGD发生率低于常规组（P < 0.05）。与治疗前相比，抗生素治疗后对照组的操作分类单位（OTU）数量显着减少，而常规和双剂量组则稳定。物种丰度，尤其是副拟杆菌属、芽孢杆菌属和罗斯氏菌属，双剂量组高于常规组和对照组。BIFICO 可能以剂量依赖的方式减少 AIGD 的发生，并能稳定肠道菌群平衡。